Navigation Links
Jubilant and Endo Pharmaceuticals Announce Successful Delivery of Early Milestones in Collaborative Discovery Program
Date:2/9/2012

BANGALORE, India, February 9, 2012 /PRNewswire/ --

Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford, Pa., USA-based Endo Pharmaceuticals that has nominated a candidate into full development. The novel molecule, targeting cancer, is anticipated to go into clinical trials by late 2012. Jubilant and Endo will continue the collaboration in the development phase as well.  

The multi-target collaboration that began three years ago focuses on Best in Class differentiated therapies to address the unmet needs of cancer patients worldwide.  The collaboration has since delivered multiple milestones across the discovery phase.  Endo will pursue development and commercialization of the compound, while Jubilant becomes eligible to receive development milestones.

"We are very pleased and elated with this successful outcome, which is a result of the excellent collaboration between the scientists at Endo and Jubilant," said Sri Mosur, CEO & President, Global Drug Discovery and Development, Jubilant. "Jubilant has pioneered from India, a business model based on shared risk that enables it to demonstrate the differentiated and novel outcomes that Jubilant scientists are able to deliver through accelerated and affordable innovation to its many collaborators."

Sandeep Gupta, Endo Pharmaceuticals, Senior Vice President, Discovery & Early Development , said, "I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled nomination of a development candidate ahead of schedule in less than two years since inception of this program. Initiation of this development program further validates Endo's unique collabrative drug discovery approach which aims to address unmet medical needs and improve patient outcomes."  

About Us

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.

http://www.jubilantbiosys.com

Contact For Business Queries

Narendra Kumar
+91(0)80-6662840
narendra_kumar@jubilantbiosys.com


'/>"/>
SOURCE Jubilant Biosys Ltd and Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jubilant HollisterStier Allergy Launches Allergy Industry Insights Educational Webinar Series
2. Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery
3. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
4. Jubilant Enters Research Collaboration With AstraZeneca
5. Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models
6. Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
7. Prismic Pharmaceuticals Acquires Scaristas Exclusive License to Amarins Omega-3 Patents for CNS Disorders
8. Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
9. Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
10. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
11. Generic Pharmaceuticals Market - A Global Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Apple Rehab ... services, staged a mock evacuation of the facility as part of a disaster drill ... Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
Breaking Medicine News(10 mins):